Kate Haviland is the President and CEO of Blueprint Medicines, a global precision therapy company. She has been instrumental in the company's growth and transformation, leveraging her extensive experience in the biopharmaceutical industry. Under her leadership, Blueprint Medicines continues to innovate and develop therapies for cancer and blood disorders.
Who is the CEO of Blueprint Medicines?
Kate Haviland, the President and CEO of Blueprint Medicines, has a rich background in the biopharmaceutical industry. She joined Blueprint Medicines in January 2016 as Chief Business Officer and later served as Chief Operating Officer from January 2019 until her appointment as CEO in April 2022. Before her tenure at Blueprint Medicines, Haviland held significant roles at Idera Pharmaceuticals, Sarepta Therapeutics, and PTC Therapeutics. She has a Bachelor of Arts from Wesleyan University and an MBA from Harvard Business School.
Her leadership has been pivotal in transforming Blueprint Medicines into a fully integrated business, driving global capital investment plans, and managing critical business functions.
Work History
Kate Haviland's extensive career in the biopharmaceutical industry includes a variety of significant roles at several prominent companies. Here is a detailed list of her work history:
- Blueprint Medicines - Chief Executive Officer (April 2022 - Present)
- Blueprint Medicines - Chief Operating Officer (February 2019 - April 2022)
- Blueprint Medicines - Chief Business Officer (January 2016 - February 2019)
- Fulcrum Therapeutics - Chairman Of The Board Of Directors (June 2018 - Present)
- Idera Pharmaceuticals - Vice President Rare Diseases and Oncology Program Leadership (April 2014 - December 2015)
- Sarepta Therapeutics - Head of Commercial Development (June 2012 - April 2014)
- PTC Therapeutics - Executive Director, Commercial Development (March 2007 - June 2012)
- Genzyme Corporation - Senior Manager (January 2006 - January 2007)
- Genzyme Corporation - Principal, Corporate Development (January 2005 - January 2006)
- PA Consulting - Consultant (January 2000 - January 2003)
- Charles River Associates - Associate (January 1998 - January 2000)
Education History
Kate Haviland's educational journey began at Wesleyan University, where she earned a Bachelor of Arts in Biochemistry/Molecular Biology and Economics, studying from January 1994 to January 1998. She furthered her education at Harvard Business School, attending from January 2003 to January 2005, where she completed her MBA. This strong academic foundation has undoubtedly contributed to her successful career in the biopharmaceutical industry.
When did Kate Haviland join Blueprint Medicines?
Kate Haviland joined Blueprint Medicines in January 2016, initially taking on the role of Chief Business Officer. She was later promoted to Chief Operating Officer in February 2019, a position she held until April 2022. On April 1, 2022, she ascended to the role of Chief Executive Officer. As of now, Haviland has been with Blueprint Medicines for over eight years, contributing significantly to the company's growth and strategic direction.